MGC Pharmaceuticals – spoof trial results fool the morons, but surely it is placing ahoy?
By Tom Winnifrith | Thursday 16 June 2022
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.
The last quarterly report from MGC Pharmaceuticals (MXC) showed that, as of 31 March, it had cash of just A$ 4.004 million - having spunked just over A$ 3.9 million in that quarter. You can do the maths…
Premium content is for paid subscribers only
ShareProphets is reader-supported journalism
Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.